Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs W W Grainger Inc (GWW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs W W Grainger Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while W W Grainger Inc trades at $1,375.73 (market cap $64.95B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays a 0.67% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GWW | |
|---|---|---|
Market Cap | $39.89B | $64.95B |
Sector | Health | Technology |
52-Week High | $491.22 | $1.38K |
52-Week Low | $278.09 | $918.18 |
Enterprise Value | $38.15B | $67.04B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GWW trades at $1,375.76, up 0.8% recently, with a bullish technical signal from moving averages and strong support at $1,356. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised full-year guidance, reflecting robust MRO demand. Revenue growth to $18.4B in 2026 and a high ROE of 48.1% underscore operational strength, though valuation multiples like P/E of 36.99 appear elevated relative to historical norms.
Outlook is positive driven by earnings momentum and dividend consistency, but risks include high valuation sensitivity and industrial sector cyclicality. Analyst consensus is mixed with a $1,260 price target, suggesting cautious optimism amid growth execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
